Not_yet_recruitingNCT07358637

Artificial Intelligence Enhanced Optical Coherence Tomography (AI-OCT) Imaging for Pre-surgical Margin Detection of Basal Cell Carcinoma

Sponsor: Henry Ford Health System

Trial Details

Condition	Basal Cell Carcinoma of Skin
Intervention	AI-OCT
Status	Not_yet_recruiting
Participants	30
Est. Completion	1 Dec 2027
Last Updated	6 May 2026

Primary Outcome

Validation of AI-OCT as an accurate method for detecting basal cell carcinomas

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * Male or Female, ages 18 or older * at least one biopsy proven superficial or nodular BCC * willingness to have photographs taken of the treatment area * ability to understand and willingness to sign a written informed consent document Exclusion Criteria: * infiltrative, micronodular, or morpheaform BCC * pregnant women * subjects not willing to have a biopsy taken from the treatment area * subjects with herpes simplex virus infection in the treatment area

View Registry Entry

Related Analysis

AI-Enhanced OCT Trial Opens: Pre-Surgical Margin Detection for Basal Cell Carcinoma — Potential to Reduce Mohs Surgery Stages

New AI-enhanced optical coherence tomography trial aims to improve pre-surgical margin detection for basal cell carcinoma, potentially reducing Mohs surgery stages and healthcare costs. Study validates diagnostic accuracy before surgical implementation.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service